Journal of Clinical Toxicology
Open Access
ISSN: 2161-0495
ISSN: 2161-0495
Li Hong yu
Associate Professor
The University of Arizona, USA
Dr. Li received his PhD degree from the University of Tokyo. He did the postdoctoral training at Columbia University and Harvard University. Dr. Li has extensive experience in drug discovery and development with a particular focus on Oncology. He has led medicinal chemistry teams with over twenty chemists and collaborated with leaders in pharmacology toxicology pharmacokinetics pharmacy and intellectual property for the discovery of new experimental drugs IND. He and his team have successfully discovered three small molecule kinase inhibitors with acceptable toxicology profile that were tested in clinical trials. Dr. Li was the kinase platform drug design leader at Eli Lilly and was responsible for the generation of kinase inhibitors His broad expertise in the study of kinases and cancer will allow him to discover the next generation kinase inhibitors for use in cancer and Alzheimer’s disease.
Dr. Li received his PhD degree from the University of Tokyo. He did the postdoctoral training at Columbia University and Harvard University. Dr. Li has extensive experience in drug discovery and development with a particular focus on Oncology. He has led medicinal chemistry teams with over twenty chemists and collaborated with leaders in pharmacology toxicology pharmacokinetics pharmacy and intellectual property for the discovery of new experimental drugs IND. He and his team have successfully discovered three small molecule kinase inhibitors with acceptable toxicology profile that were tested in clinical trials. Dr. Li was the kinase platform drug design leader at Eli Lilly and was responsible for the generation of kinase inhibitors His broad expertise in the study of kinases and cancer will allow him to discover the next generation kinase inhibitors for use in cancer and Alzheimer’s disease.